 Connection
Bradley Dixon to Atypical Hemolytic Uremic Syndrome
This is a "connection" page, showing publications Bradley Dixon has written about Atypical Hemolytic Uremic Syndrome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.020 |
|
|
|
-
Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul; 47(7):1081-1087.
Score: 0.803
-
Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2018 06; 65(3):509-525.
Score: 0.617
-
Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 09; 12(9):e230036.
Score: 0.221
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
Score: 0.184
-
Fraga-Rodriguez GM, Bri?-Sanagustin S, Tur?n-Vi?as E, Dixon BP, Carreras-Gonz?lez E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep. 2017 Apr 26; 2017.
Score: 0.143
-
Stenson EK, Kendrick J, Dixon B, Thurman JM. The complement system in pediatric acute kidney injury. Pediatr Nephrol. 2023 05; 38(5):1411-1425.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|